Combined immunization with human papillomavirus type 18 fusion protein and recombinant vaccinia virus in mice
10.3760/cma.j.issn.1003-9279.2018.04.003
- VernacularTitle: 人乳头瘤病毒18型融合蛋白和重组痘苗病毒联合免疫的效果评价
- Author:
Li ZHAO
1
;
Jiao REN
1
;
Jing FENG
2
;
Zheng PANG
1
;
Panpan HUANG
1
;
Ying ZHAO
1
;
Wenjie TAN
1
;
Li RUAN
1
;
Houwen TIAN
1
Author Information
1. Key Laboratory of Medical Virology and Viral Disease, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
2. National Vaccine and Serum Institute, Beijing 100176, China
- Publication Type:Journal Article
- Keywords:
Human papillomavirus;
Cervix neoplasms;
Vaccine;
Immunization therapy
- From:
Chinese Journal of Experimental and Clinical Virology
2018;32(4):347-351
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the cellular and humoral immune responses induced by combined immunization with the fusion protein of human papillomavirus type 18 (HPV18) and the recombinant vaccinia virus.
Methods:Purified HPV18L231-600E7E6 fusion protein, expressed by prokaryotic expression system, were immunized in combination with the recombinant vaccinia virus vaccine expressing HPV18E7E6 fusion protein (rVV18E7E6) by using various prime-boost regiments in C57BL/6 mice. Cellular and humoral immune responses were analyzed by enzyme-linked immunospot assay (ELISPOT), enzyme-linked immunosorbent assay (ELISA), and pseudovirus neutralization assay.
Results:Higher levels of cellular immune responses were induced in mice primed with the HPV18L231-600E7E6 fusion protein/adjuvant CpG and boosted with the recombinant vaccinia virus rVV18E7E6, than in other immunized mice. Higher binding antibody level was induced, and low level neutralizing antibody against pseudovirus was detected simultaneously.
Conclusions:Priming with HPV18L231-600E7E6 fusion protein/CpG and boosting with the recombinant vaccinia virus rVV18E7E6 could induce higher cellular and humoral immune response in immunized mice, which might be taken as vaccine candidate for treatment of HPV18 chronic infection and postoperative adjuvant treatment for cervical cancer.
